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The p53 homolog p63 is essential for development,
yet its role in cancer is not clear. We discovered
that p63 deficiency evokes the tumor-suppressive
mechanism of cellular senescence, causing a striking
absence of stratified epithelia such as the skin. Here
we identify the predominant p63 isoform, DNp63a,
as a protein that bypasses oncogene-induced
senescence to drive tumorigenesis in vivo. Interest-
ingly, bypass of senescence promotes stem-like
proliferation and maintains survival of the keratin
15-positive stem cell population. Furthermore, we
identify the chromatin-remodeling protein Lsh as
a new target of DNp63a that is an essential mediator
of senescence bypass. These findings indicate that
DNp63a is an oncogene that cooperates with Ras
to promote tumor-initiating stem-like proliferation
and suggest that Lsh-mediated chromatin-remodel-
ing events are critical to this process.
INTRODUCTION
Deregulation of intrinsic tumor-protective mechanisms can
convert normal epithelia into malignant carcinoma and lies at
the heart of the majority of human cancers. p53 is a pivotal regu-
lator that protects from such events. Therefore, the discovery of
the p53 family members p63 and p73 generated much interest
that these proteins would also act to prevent cancer.
However, with regards to p63, a more complicated picture has
emerged. p63 is expressed robustly in stem and progenitor cells
within the proliferating basal layer of stratified epithelia such as
the skin, breast, and prostate. p63’s critical importance in
epithelia is highlighted by p63-deficient mouse models. In
contrast to the viable and fertile, yet tumor-prone, phenotype
of p53-deficient mice (Donehower et al., 1992; Jacks et al.,
1994), p63-deficient mice die postnatally from severe develop-
mental anomalies, including a lack of skin and associated deriv-
atives, an absence of glands such as prostate and breast, and
truncation of limbs (Mills et al., 1999; Yang et al., 1999).We previ-164 Cell Stem Cell 8, 164–176, February 4, 2011 ª2011 Elsevier Inc.ously circumvented this postnatal lethality by generating a p63
conditional mouse model (Mills et al., 2002) and reported that
inducible ablation of p63 in primary keratinocytes in culture
induces a program of cellular senescence and that ablation of
p63 in proliferating cells of the adult epidermis in vivo induces
cellular senescence and accelerated aging, establishing that
p63 deficiency-mediated cellular senescence is a cause of
organismal aging (Keyes et al., 2005).
Despite these advances, the role of p63 in cancer has re-
mained perplexing, in large part because multiple p63 isoforms
exist. p63 proteins can be classified into two main groups,
each of which is transcribed from distinct promoters: those pos-
sessing a full-length transactivation domain analogous to that of
p53 (referred to as the TA isoform class) and those lacking this
domain (referred to as the DN isoform class) (Yang et al.,
1998). Alternative splicing at the carboxy terminus generates
three splice variants (a, b, g) within each group. The tumorigenic
potential of p63-deficient mice has surprisingly not helped to
clarify the role of p63 in cancer, because different groups have
reported disparate results (Flores et al., 2005; Keyes et al.,
2006). In addition, the p63 mouse models used for tumor studies
thus far are deficient for all p63 isoforms, and therefore the
contribution of individual p63 proteins in cancer may have
been masked in these studies. Indeed, it has been suggested
that the TA isoforms are most similar to p53, whereas theDN iso-
forms have opposing functions. DNp63a is the predominant iso-
form expressed in stem cells as well as in proliferating basal cells
of stratified epithelia (Yang et al., 1998). DNp63a is overex-
pressed in some types of human cancer, particularly squamous
cell carcinoma (SCC) (Hibi et al., 2000; Tonon et al., 2005), and it
has been suggested to have oncogenic functions through inhibi-
tion of p53 (Yang et al., 1998). However, in other tumor types,
such as adenocarcinoma of the breast and prostate, DNp63a
expression is lost during the tumorigenic process (Di Como
et al., 2002).
Thus, the role of p63 in cancer, and in particular the role of indi-
vidual p63 isoforms, merits further investigation. Given our
previous findings that p63 deficiency induces cellular senes-
cence, we hypothesized that p63 might also be a key modulator
of the tumor-suppressive mechanism of oncogene-induced
senescence (OIS). We explored the role of p63 in OIS—specifi-
cally with activated Ras being the oncogene—with a system
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models. Herewe demonstrate that the predominant p63 isoform,
DNp63a, is an oncogene that promotes stem-like proliferation
and carcinoma development through induction of the chromatin
remodeler Lsh.
RESULTS
Downregulation of DNp63a Is Required
for Oncogene-Induced Senescence
To investigate a potential role for p63 in OIS, we induced senes-
cence in primary mouse keratinocytes by retroviral infection with
oncogenic H-Ras-V12 (hereafter referred to as Ras) and moni-
tored p63 expression. As shown previously, Ras induced
features of senescence, including proliferation arrest, a charac-
teristic morphology, and enhanced senescence-associated
b-galactosidase (SA-b-gal) activity (Figure 1; Serrano et al.,
1997). Interestingly, induction of senescence was concomitant
with a significant decrease in expression of endogenous
DNp63a expression at both the transcript and protein level,
whereas expression of TAp63 isoforms was not affected (Fig-
ure 1A; Figure S1 available online). This demonstrates that the
predominant p63 isoform expressed in keratinocytes, DNp63a,
is depleted during OIS.
To determine whether loss ofDNp63a is a requirement for OIS,
primary keratinocytes were coinfected with Ras and expression
constructs encoding DNp63a, TAp63a, or mutant DNp63a
(DNp63aR279H). The R279H mutation within the DNA binding
domain of p63 causes EEC syndrome in humans and corre-
sponds to one of the most prevalent p53 point mutations found
in human cancer (Celli et al., 1999). Whereas expression of
DNp63a was sufficient to inhibit senescence and induce
continued proliferation in Ras-expressing primary keratinocytes,
neither TAp63a nor DNp63aR279H had this ability (Figures 1B–
1D). These data demonstrate that downregulation of DNp63a
is necessary for OIS and that overexpression of this isoform
bypasses senescence.
DNp63a Cooperates with Oncogenic Ras to Promote
Stem-like Proliferation
Keratinocytes expressing Ras and DNp63a (hereafter referred to
as RDN cells) had a specific cellular phenotype: whereas shortly
after infection they failed to senesce and continued to proliferate
slowly, approximately 2 weeks after infection, clonal populations
of proliferating cells emerged from these cultures. Given that p63
has been proposed as a determinant of epithelial stem cells (Se-
noo et al., 2007), we askedwhether the clonally proliferating RDN
cells that had bypassed senescence had characteristics of stem
cells.We grewRDNcells in three-dimensional (3D) culture condi-
tions designed to assay for the self-renewal capability and prolif-
erative potential of stem cells (Figure 2A; Lawson et al., 2007).
Whereas vector- or Ras-infected cells failed to proliferate in 3D
culture, cells infected withDNp63a proliferated and formed clus-
ters containing small numbers of cells. In contrast, the clonal
RDN cells that had bypassed senescence proliferated robustly
in 3D culture, forming largemulticellular spheres. To test whether
this sphere-forming capability was a universal feature of cells
that had escaped senescence, we inhibited OIS by shRNA-
mediated knockdown of p53 in the presence of Ras (referredCto as Rshp53 cells) and analyzed for growth in 3D culture.
Rshp53 cells proliferated robustly and formed large irregular
growths, but were devoid of the sphere-forming ability observed
in RDN cultures (Figure 2A). This suggested that the 3D sphere
phenotype of RDN keratinocytes resulted from a unique cooper-
ation between DNp63a and Ras. Immunofluorescent analysis
demonstrated that whereas RDN spheres expressed markers
of proliferating keratinocytes such as keratin 14 (K14), indicating
that they were relatively undifferentiated, Rshp53 cells ex-
pressed significantly lower levels of K14 (Figure 2B).
A hallmark feature of stem cells is their ability to self-renew. To
assess the self-renewal potential of RDN 3D cultures, primary
spheres were either dissociated and replated directly into the
3D culture (data not shown) or were first expanded as a mono-
layer and then replated into 3D culture (Figure S2A). In each
case, RDN cells retained their sphere-forming capability,
whereas Rshp53 cells did not have this property. This demon-
strates that DNp63a’s ability to bypass senescence endows
keratinocytes with intrinsic self-renewal capabilities that are
characteristic of stem-like cells.
Genes whose expression is elevated in the keratinocyte stem
cell populations of mouse skin have been identified (Blanpain
et al., 2004; Mignone et al., 2007; Tumbar et al., 2004). Interest-
ingly, real-time RT-PCR indicated that 3D cultures of RDN cells
expressed elevated levels of a number of stem cell markers rela-
tive to Rshp53 cells, including s100a6, Idb2, Notch, and Tcf3
(Figure S3B). By using FACS analysis to identify the CD34/a-6
integrin double-positive stem cells, we found that the RDN
cultures expressed higher levels of the epithelial stem cell
markers CD34 and a6-integrin than control cultures (not shown).
This demonstrates that DNp63a acts in concert with oncogenic
Ras to promote proliferation of cells with enhanced expression
of stem cell-associated genes.
Another key feature of stem cells is their ability to differentiate.
We askedwhether RDN cells have this capacity by taking advan-
tage of the ability of primary keratinocytes to terminally differen-
tiate and to withdraw from the cell cycle in the presence of
elevated calcium (Dotto, 1999).Whereas wild-type keratinocytes
lose their epithelial phenotype, acquire a differentiated
morphology, and lose expression of proliferation markers such
as PCNA upon calcium addition, cells transformed by Rshp53
fail to undergo such differentiation, proliferate robustly, and
readily formmultiple foci (Figure 2C). Remarkably, RDN keratino-
cytes were unique: they were similar to wild-type cells with re-
gard to their ability to acquire phenotypic features of terminal
differentiation in response to elevated calcium, yet in contrast
to wild-type keratinocytes, they did not withdraw from the cell
cycle and continued to proliferate. Consistent with these cellular
phenotypes, real-time RT-PCR analyses for a panel of markers
of epithelial proliferation and differentiation indicates that RDN
cells retain both proliferative and differentiation potential (Fig-
ure 2D; Figure S2C). These findings demonstrate that whereas
both p53 loss and DNp63a overexpression facilitate bypass of
the tumor-suppressive mechanism of OIS, DNp63a-mediated
bypass is unique in that it facilitates proliferation while retaining
the capacity to differentiate.
The ability of DNp63a to enhance stem-like characteristics in
the presence of oncogenic Ras could be due to expansion of
the normal epithelial stem cell population or alternatively couldell Stem Cell 8, 164–176, February 4, 2011 ª2011 Elsevier Inc. 165
Figure 1. Downregulation of DNp63a Is Required for Oncogene-Induced Senescence
(A) Primary mouse keratinocytes were infected with retrovirus expressing GFP-vector (control) or oncogenic HRasV12 (Ras), with Ras-infected cells undergoing
oncogene-induced senescence (left). qPCR (upper right) and western blot (lower right) analysis 7 days postinfection indicates that DNp63 is downregulated at
both the transcript and the protein level in senescent cells. DNA binding domain, DBD;DN,DNp63 isoforms; Uninfected, U; Control, C; Ras , R. Quantitation ± SD.
Scale bars represent 50 mm.
(B) Keratinocytes were infected with retroviral Ras (R) or were coinfected with Ras as well as GFP-expressing DNp63a (RDN), TAp63a (RTA), or DNp63aR279H
(RDNR279H) constructs. Cells expressing Ras and DNp63a continue to proliferate. Scale bars represent 50 mm.
(C) Senescence-associated-b-galactosidase (SA-b-Gal) assay and quantitation shows decreased senescence in cells expressing Ras+DNp63a. Scale bars
represent 50 mm.
(D) Western blotting showing expression of p63, Ras, and actin in infected cells.
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Figure 2. DNp63a’s Ability to Bypass OIS Leads to Proliferation of Cells with Stem-like Properties
(A) Primary keratinocytes infected with Ras+DNp63a-GFP form spheres in 3D tissue culture, while cells infected with vector, Ras, DNp63a, or Ras and a short-
hairpin specific for p53 (shp53) do not have this ability.
(B) Immunofluorescence on 3D cultures shows elevated K14 expression in Ras+DNp63a spheres compared to Ras+shp53 cultures.
(C) Primary keratinocytes expressing a GFP construct (vector) proliferate in low-calcium media but terminally differentiate and stop proliferating in high-calcium
conditions, as shownwithwestern blot for PCNA (right). Cells infectedwith Ras+DNp63a acquire the samemorphological changes with calcium treatment, but do
not stop proliferating, whereas cells expressing Ras+shp53 do not acquire the same differentiation features and remain proliferative.
(D) qPCR for markers of basal epithelia (keratin 14), early differentiation (keratin 10), and late differentiation (involucrin) show that cells expressing Ras+DNp63a
differentiate in response to calcium, similar to early differentiation in vector-expressing cells. Ras+shp53 cells have decreased keratin markers and do not differ-
entiate. Error bars are ±SEM.
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differentiated transit-amplifying cell population. To determine
whether DNp63a was affecting the normal stem cell population,
we used two different mouse models that mark two distinct
CD34-positive epithelial stem cell populations of the skin
in vivo. The first model is the keratin 15 (K15)-GFP mouse, inCwhich the K15 promoter drives GFP expression in stem cells of
the hair follicle bulge that can give rise to all epidermal cell types
(Morris et al., 2004). The secondmodel is theNestin-GFPmouse,
in which the Nestin promoter drives GFP expression in multipo-
tent CD34-positive, K15-negative stem cells of the hair follicle
bulge, which have the capacity to differentiate into multipleell Stem Cell 8, 164–176, February 4, 2011 ª2011 Elsevier Inc. 167
Figure 3. Ras and DNp63a Expression Maintains Survival of K15-Expressing Stem Cells
(A) Whole-mount immunofluorescence of the bulge region of adult mouse skin identifies keratin15 (green)- and Nestin (red)-positive stem cell populations in the
bulge region of the hair follicle. The K15-positive population is visualized with a K15 antibody; the Nestin-positive population is covisualized by immunofluores-
cence with a GFP-specific antibody in Nestin-GFP transgenic mice. Sebaceous glands (sg) label nonspecifically.
(B) FACS analyses of primary keratinocyte cultures derived from K15-GFP transgenic mice after infection with vector or Ras+DNp63a. After 14 days, cells
infected with vector are not maintained and GFP-positive stem cells are depleted. However, cells infected with Ras+DNp63a maintain the GFP-positive stem
cells 14 days after infection.
(C) Quantification of FACS experiments (K15, n = 5; Nestin, n = 9) showing a loss of K15-positive stem cells infected with vector control after 14 days. In contrast,
the GFP-positive stem cell population is maintained by Ras+DNp63a (top). Similar experiments showNestin-GFP-positive stem cells (bottom) are not maintained
by either vector or Ras+DNp63a. Error bars are ±SEM.
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adipogenic capacity (Mignone et al., 2007). In both models,
GFP-negative cells include committed, more differentiated
transit-amplifying cells. Although both K15- and Nestin-positive
stem cell populations are prevalent in the hair follicles of the
bulge region, these markers identify distinct stem cell popula-
tions in adult skin (Figure 3A). We evaluated the effect of RDN
on both models by establishing primary keratinocytes from
newborn skin from K15-GFP and Nestin-GFPmice and infecting
with control vectors or Ras plus DNp63a expression constructs.
To evaluate whether the GFP or the non-GFP populations were
being affected by DNp63a, we assessed the percentage of
GFP-expressing cells, specifically looking during both senes-
cence bypass and the clonal expansion stage (Figures 3B and168 Cell Stem Cell 8, 164–176, February 4, 2011 ª2011 Elsevier Inc.3C). As expected, the control vector did not confer a proliferative
advantage to either the K15- or Nestin-marked stem cell pools,
and these cells failed to proliferate 7 days after infection, as is
typical for primary mouse keratinocyte cultures. In contrast,
the K15-positive (but not the Nestin-positive) stem cell popula-
tion was maintained in proliferating RDN keratinocytes that had
bypassed senescence, even 25 days after infection. These
results indicate that DNp63a cooperates with oncogenic Ras
to maintain the K15-positive stem cell population.
DNp63a Is an Oncogene that Promotes Tumor
Formation
Our results demonstrate that expression of DNp63a inhibits OIS
and promotes proliferation of cells with properties of stem cells.
Figure 4. DNp63a Is an Oncogene that Cooperates with Oncogenic
Ras In Vivo
(A) Whole-animal imaging of nude mice injected subcutaneously with primary
keratinocytes expressing Ras+shp53-GFP or Ras+DNp63a-GFP shows the
development of GFP-expressing tumors.
(B) Pathological and immunohistological analyses demonstrate distinct tumor
types. Ras+shp53 tumors present mainly as fibrosarcoma lacking expression
of epithelial markers, whereas Ras+DNp63a tumors are squamous cell carci-
nomas expressing p63, K14, and b-catenin.
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stem-like features, have been suggested to be the cell-of-origin
for a number of tumor types. Mutations that impair senescence
can facilitate malignancy, so we asked whether primary cells in-
fected with RDN were transformed and tumorigenic in vivo. As
positive controls, primary keratinocytes infected with Ras and
shRNA-p53-GFP were injected subcutaneously into nude
mice. Imaging and analysis of these mice revealed the growth
of GFP-positive tumors with the expected high incidence for
cells transformed by p53 deficiency in the context of Ras (overall
tumor incidence, 17/18 sites, 94%) (Figure 4A; Table S1). Injec-
tion of cells infected with either vector, Ras alone, or DNp63aCalone did not yield any tumors, in agreement with previous
results (Table S1; Missero et al., 1996). Strikingly, RDN cells
also formed GFP-positive tumors, albeit with a lower overall inci-
dence (12/24 sites, 50%) (Figure 4A; Table S1), indicating that
DNp63a is an oncogene that induces tumorigenesis in coopera-
tion with oncogenic Ras.
Histopathological analyses of tumors that developed in vivo
revealed that RDN expression caused tumors that were histolog-
ically distinct from those in which p53 was knocked down, even
though the same preparations of cells that had been cultured
under identical conditions in parallel were used. Tumors that
developed from Rshp53 cells were large, rapidly growing hard
masses and presented primarily as fibrosarcoma or poorly differ-
entiated sarcoma, with features of having undergone epithelial-
mesenchymal transformation (EMT) (Figure 4B; Table S1). In
contrast, tumors that developed from RDN cells were slower
growing, often included smaller tumor masses surrounded by
necrotic tissue, and presented predominantly as SCC, with
some mice developing poorly differentiated sarcoma. Immuno-
histochemical analyses further demonstrated the distinction
between the different tumor types, with the RDN tumors ex-
pressing the epithelial markers K14 and b-catenin, while these
epithelial markers were not detectable in Rshp53 tumors (Fig-
ure 4B; Figure S3A). Interestingly, N-cadherin, a marker of
EMT, was detectable in only a few cells of RDN tumors, but
was expressed robustly throughout Rshp53 tumors (Figure S3A),
suggesting that RDN had not undergone EMT. Furthermore,
whereas immunostaining for p53 and p19 showed that p53-defi-
cient tumors had elevated p19 expression, indicating that p53-
mediated feedback inhibition of p19 was impaired, RDN tumors
were also deficient for p53, but p19 was not detectable in these
tumors (Figure S3B). This further demonstrates the histological
and molecular distinction between these tumors. These findings
are in agreement with the high incidence and early expression of
DNp63a in human SCC (Hibi et al., 2000), demonstrating that
DNp63a is an oncogene capable of causing tumor development
in a manner distinct from deficiency of p53.
Downregulation of p63 Occurs in Senescent Cells
of Premalignant Lesions In Vivo
To extend our findings that p63 depletion is a prerequisite for
OIS, we monitored expression of endogenous p63 in vivo in
a model of OIS bypass-induced carcinogenesis. Topical treat-
ment of mouse skin with DMBA induces Ras mutations, which
facilitate development of premalignant papillomas with markers
and features of OIS; inactivation of mediators of OIS facilitates
senescence bypass and converts preneoplastic lesions tomalig-
nant SCC (Collado et al., 2005). We examined skin sections from
DMBA-induced papillomas and SCC for expression of p63 and
markers of senescence. p63 was detectable in premalignant
lesions, as previously shown (Keyes et al., 2006), but notably
was most robust in the proliferating basal layer, with expression
decreasing in suprabasal layers (Figure 5), analogous to the
graded pattern of p63 observed in normal skin. This contrasts
markedly with p63 expression in SCC, which is abundant in
transformed cells that escaped senescence and progressed to
malignancy (Figure 5A). To examine whether the decrease in
p63 expression in the premalignant lesions correlated with cells
that had undergone OIS, tissues were costained for p63 as wellell Stem Cell 8, 164–176, February 4, 2011 ª2011 Elsevier Inc. 169
Figure 5. Downregulation of Endogenous p63
Occurs in Senescent Cells of Premalignant
Lesions In Vivo
(A) Papilloma and SCC were induced by treating mouse
skin with DMBA. In papillomas, p63 expression is
restricted to the basal layer, but decreases in the lesion,
whereas p63 is expressed in all cells that progressed to
squamous cell carcinoma (SCC). The schematic highlights
areas of proliferation (P), senescence (S), and tumor (T).
(B) Immunohistochemical analyses of premalignant papil-
lomas indicate that Ki67 and p63 are coexpressed in the
basal layer but are absent in the nonproliferative region
where the senescence markers gH2AX and p19 are ex-
pressed. The schematic highlights areas of proliferation
(P) and senescence (S).
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Whereas expression of p63 overlapped with the proliferation
marker Ki67, it did not overlap with the senescence markers
gH2AX and p19. This indicates that OIS in vivo occurs in p63-
depleted cells, whereas cells that bypass senescence and
develop into tumors express p63 robustly. The finding that the
patterns of expression of p63 and markers of senescence are
mutually exclusive in vivo confirms and extends our findings
that downregulation of endogenous DNp63a is required for OIS.
Lsh Is a p63 Target Gene
To elucidate the mechanism by which DNp63a inhibits OIS, we
examined primary keratinocytes that had been infected with
RDN or control vectors shortly after infection (see schematic,
Figure 6A). This time point precedes the development of distinct
cellular phenotypes and was chosen because we wanted to
identify DNp63a-modulated pathways that initiated senescence
bypass and led to stem-like proliferation and tumorigenesis. We
examined expression of known senescence mediators at the
transcript and protein level in RDN cells; however, p53, p16,
p19, p21, and PML were not reduced during the initial stages
of senescence bypass (Figures 6B; Figure S4A). These analyses170 Cell Stem Cell 8, 164–176, February 4, 2011 ª2011 Elsevier Inc.not only indicate that the initiating events by
which DNp63a inhibits senescence probably
do not occur via these pathways, but it also
suggests that additional as yet uncharacterized
senescence pathways are modulated by
DNp63a.
To identify genes whose expression was
altered by DNp63a expression and hence might
reveal novel DNp63a-mediated pathways facili-
tating senescence bypass, we performed cDNA
microarray analyses on primary keratinocytes at
an early stage after infection with RDN and
controls. This led to the identification of 26
genes whose expression was either increased
(23 genes) or decreased (3 genes) in RDN cells
relative to controls (Figure S4B). Real-time RT-
PCR confirmed that expression of a number of
these genes was altered in RDN cells, indicating
that these genes are induced during the initial
phase of senescence bypass.To determine whether any of the candidate genes were direct
targets of DNp63a, we analyzed the regions upstream of the
transcriptional start sites for p53/p63 consensus binding sites.
We identified a p63-consensus binding site in the mouse Lsh
(lymphoid-specific helicase) gene (Figure S5A), which encodes
a member of the SNF2 family of chromatin remodeling proteins.
Like p63, Lsh has been implicated in both embryonic develop-
ment and cellular senescence (Geiman et al., 2001). Analysis of
the human LSH promoter identified putative p63 consensus
binding sites similar to those described previously (Figure S5B;
Yang et al., 2006). To determine whether p63 binds the Lsh
promoter, we performed chromatin immunoprecipitation (ChIP)
in RDN cells with an antibody specific for p63. Primers for p21,
a previously identified DNp63a target gene, were used as a posi-
tive control (Figure 6C). By using multiple primer pairs flanking
the p63 consensus binding site identified in Lsh, we found that
p63 bound this region, whereas under similar conditions, we
did not detect binding to the promoter region of two other genes
(Figure 6C; Figure S5C). The p63 antibody used for ChIP was
raised against a peptide common to each of the six p63 isoforms
(Yang et al., 1998). To determine which p63 isoform was prob-
ably directly regulating Lsh, we performed western analyses of
Figure 6. Lsh Is a p63 Target Gene
(A) Timeline schematic of the experimental procedure. Phase I corresponds
with initiating events leading to senescence bypass, whereas phase II involves
clonal proliferation of stem-like cells and tumor development.
(B) Western blotting for p63 and senescence mediators in cells expressing
Ras+DNp63a during phase 1 of senescence bypass indicates that expression
of p53, p16, PML, or p21 are not reduced.
(C) Chromatin immunoprecipitation (ChIP) analysis shows p63 is bound to the
Lsh promoter. p21 binding serves as a positive control. In, input; Ig, immuno-
globulin (negative) control.
(D) Immunofluorescence for p63 and Lsh in E17.5mouse skin shows overlap in
the basal epithelia.
(E) Primary mouse keratinocytes from two individual wild-type and p63loxP/loxP
mice were infected with retroviral vector or Cre. Expression of p63 DNA-
binding domain (DBD) is lost in p63loxP/loxP cells with Cre, and Lsh expression
is decreased coordinately. Error bars are ±SEM.
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body. This analysis revealed that DNp63a is the predominant
isoform detectable in these cells (Figure S5D), supporting the
idea that Lsh is a direct target of this isoform.
To determine whether DNp63a and Lsh are expressed in the
same cell type in an in vivo setting, we assessed the pattern
of Lsh expression in embryonic day 17.5 skin, a time point
when DNp63a levels are especially robust (Figure 6D).CCoimmunostaining revealed a clear overlap between p63 and
Lsh expression in proliferating basal keratinocytes of the
epidermis, further supporting the fact that Lsh is a target of
DNp63a. To assess whether DNp63a is required for Lsh expres-
sion, we ablated p63 in primary keratinocytes obtained from the
p63 conditional mouse model that we described previously
(Keyes et al., 2005; Mills et al., 2002). Indeed, Cre-mediated
disruption caused loss of p63, while simultaneously reducing
Lsh expression at the transcript level (Figure 6E). These findings
demonstrate that the pattern of Lsh expression overlaps with
that of DNp63a in vivo and that Lsh expression is dependent
upon p63 expression, providing additional evidence for Lsh
being a direct target of DNp63a in primary keratinocytes.
Lsh Is Required for DNp63a-Mediated Senescence
Bypass
Having identified Lsh levels as being upregulated in RDN cells at
the transcript level, we examined Lsh expression at the protein
level. We prepared protein lysates from DNp63a, RDN, and
control cells 6 days after infection, at a time point prior to senes-
cence bypass when all cultures were phenotypically similar (see
Figure 6A). Western analyses indicated that Lsh protein levels
were higher in cells overexpressing DNp63a (Figure 7A). In addi-
tion, we found that in contrast to control cultures, RDN keratino-
cytes could be maintained for an extended time in culture, and
these cells expressed robust levels of Lsh (Figure S6A). These
findings further support our observations that DNp63amediates
Lsh expression and that Lsh is induced prior to, and is main-
tained after, senescence bypass.
Our findings identify Lsh as a p63 target whose expression is
induced during senescence bypass and tumor initiation. To
determine whether Lsh is required for DNp63a-mediated inhibi-
tion of OIS, we generated multiple shRNAs for Lsh. We identi-
fied one hairpin (977) that was capable of reducing Lsh levels
by about 95% (Figure 7B; Figure S6B). To test the specificity
of this hairpin, we assayed for Lsh activity by assessing reacti-
vation of repetitive elements throughout the genome—inte-
grated retrotransposons silenced by Lsh (Figure S6C; Sun
et al., 2004). A number of repeat elements (including ERVL,
MaLR, major and minor satellites, LINE1) were significantly up-
regulated in Lsh-depleted cells, providing functional evidence
that Lsh activity is compromised by RNAi-mediated knock
down.
To functionally test whether Lsh was required for DNp63a-
mediated bypass of senescence, keratinocytes were infected
with combinations of vector controls, Ras, DNp63a, and
shRNA-Lsh and the extent of RDN-mediated bypass of senes-
cence was evaluated (Figures 7B and 7C). Interestingly, whereas
knockdown of Lsh in vector control cells impaired proliferation
(Figure 7C), in agreement with the finding that deficiency of Lsh
induces senescence in vivo (Sun et al., 2004), knockdown of
Lsh in the context of DNp63a produced a stronger senescent-
like morphology, irrespective of Ras expression, a finding
consistent with Lsh being a target of DNp63a. In agreement,
a specific hairpin that did not affect Lsh levels did not have this
effect (not shown). BrdU incorporation shortly after infection indi-
cated that proliferation was significantly compromised when Lsh
was knocked down in the presence of DNp63a, with remaining
cells failing to proliferate when maintained for longer periods.ell Stem Cell 8, 164–176, February 4, 2011 ª2011 Elsevier Inc. 171
Figure 7. Lsh Is Required forDNp63a’s OIS-
Inhibiting Activity
(A) Western blotting for Lsh and p63 in primary
mouse keratinocytes expressing vector (V), Ras
(R), DNp63a (DN), and Ras+DNp63a (RDN) during
phase I senescence bypass indicates that Lsh
expression is increased in DNp63a-expressing
cells.
(B) Western blotting for Lsh and p63 in primary
mouse keratinocytes expressing vector (V),
DNp63a (DN), and Ras+DNp63a (RDN) coinfected
with retroviral vector (LMP) or shRNA-Lsh.
(C) Cell morphology by phase contrast and GFP-
fluorescence shows fewer cells and senescent-
like morphology in Lsh-knockdown cells. Immu-
nostaining for BrdU incorporation and quantitation
shows that Lsh-knockdown cells expressing
DNp63a proliferate less. BrdU quantitation, ±
SEM: one-way ANOVA/Tukey’s t test.
(D) Immunostaining indicates that p63 and Lsh are
coexpressed in DMBA-induced premalignant
papillomas in situ.
(E) Immunostaining indicates that Lsh is ex-
pressed robustly in tumors arising from subcuta-
neous injection of RDN keratinocytes, but not
those arising from subcutaneous injection of
Rshp53 keratinocytes.
(F) Western blotting shows increased Lsh
expression in two squamous cell carcinoma cell
lines (029, 011) that have increased p63 expres-
sion, compared to human primary keratinocytes
(HPK).
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mediator of senescence bypass.
To assess the relationship between endogenous p63 and Lsh
in senescence inhibition and tumorigenesis in an in vivo setting,
we analyzed the pattern of Lsh expression in DMBA-induced
premalignant papillomas. Whereas Lsh was not detectable in
normal skin of these adult animals (Figure S7A), it was robustly
expressed in the p63-positive proliferative zone of premalignant
lesions; in contrast, Lsh was not detectable in the p63-negative
senescent zone (Figure 7D). This coexpression of p63 and Lsh
in chemically induced carcinomas of the skin was in agreement
with our analyses of RDN and Rshp53 tumors obtained in nude
mice, as shown by the fact that RDN tumors had significantly
higher expression of Lsh (Figure 7E; Figure S7B). To examine
whether DNp63a and LSH expression are also coregulated in
human carcinomas, we analyzed HNSCC cell lines previously172 Cell Stem Cell 8, 164–176, February 4, 2011 ª2011 Elsevier Inc.shown to rely on enhanced DNp63a
expression (Rocco et al., 2006). Interest-
ingly, in these cell lines that overexpress
DNp63a, we found that LSH is also upre-
gulated relative to normal human kerati-
nocytes, supporting our observations
made in mouse cells (Figure 7F; Fig-
ure S7C). These data demonstrate that
DNp63a induces expression of Lsh and
support our findings that DNp63a-medi-
ated Lsh expression bypasses Ras-
induced senescence and promotesstem-like proliferation, setting the stage for carcinoma develop-
ment in vivo.
DISCUSSION
Our study identifies DNp63a as an oncogene in the skin, capable
of inhibiting oncogene-induced senescence and promoting
development of squamous cell carcinoma. There has been
much confusion about the role of p63 in tumorigenesis. Unlike
p53, point mutations in p63 are rarely associated with cancer,
but cause a spectrum of developmental birth defects (Brunner
et al., 2002). In further contrast to p53, the predominant p63 iso-
form detectable in proliferating epithelia, DNp63a, is frequently
overexpressed in a variety of human tumors, particularly SCC
of the skin, head and neck, and lung (Hibi et al., 2000; Tonon
et al., 2005), although an oncogenic role for DNp63a had not
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p63 and Lsh Promote Tumor-Initiating Stem Cellsbeen demonstrated previously. In the context of cultured cells,
DNp63a was suggested to promote oncogenesis by inhibiting
p53 activity (Yang et al., 1998), though this has not been demon-
strated in vivo. However, we found that primary epithelial cells
transformed with these different genetic lesions give rise to cells
and tumors with different properties, suggesting that DNp63a
promotes tumor development through p53-independent mecha-
nisms. Our data now conclusively show that gain of DNp63a
activity is a causative lesion that cooperates with oncogenic
Ras to promote tumorigenesis. Furthermore, the ability of
DNp63a to inhibit OIS provides mechanistic insight that explains
why overexpression of this isoform in human tumors is an early
and highly penetrant event.
We had previously discovered that the apparent tumor protec-
tion in p63-compromisedmice comes at the expense of reduced
lifespan (Keyes et al., 2005). Furthermore, conditional ablation of
p63 in stratified epithelia does not induce tumorigenesis (Mills
et al., 2002; W.M.K. and A.A.M., personal observation), but in
contrast, activates the tumor-suppressive mechanism of cellular
senescence, interestingly, with features of accelerated aging
(Keyes et al., 2005). This provided functional evidence that
cellular senescence and aging are linked in vivo and exemplified
p63’s role in this process. All p63 proteins were ablated in these
studies, so the contribution of individual p63 isoforms was not
established. We hypothesized that loss of DNp63a was respon-
sible for p63 deficiency-induced cellular senescence, an idea
supported by the finding that DNp63a regulates epithelial
stem/progenitor cells within the epidermis (Senoo et al., 2007).
A recent report suggests that the TAp63 isoforms also function
to regulate senescence within a different stem cell niche, inhibit-
ing cellular senescence in skin-derived progenitor cells (SKPs)
(Su et al., 2009)—a progenitor population that gives rise to
neuronal and mesenchymal cell types, but not to epithelial cell
types such as keratinocytes (Fernandes et al., 2008; Toma
et al., 2005). In yet another setting—fibroblasts—TAp63 isoforms
induce cellular senescence in a p53-independent manner (Guo
et al., 2009). These data highlight the roles of p63 in specific
stem/progenitor cell populations of distinct tissues, as we now
show occurs in tumor-initiating stem-like cells. The findings
that distinct p63 isoforms regulate cellular senescence differ-
ently within diverse settings suggest that although senescence
is a program that has common mediators and pathways, there
are underlying tissue-specific mechanisms at play.
A major finding of this study is that it identifies DNp63a as an
inhibitor of OIS. OIS is a tumor-suppressive mechanism that
curtails aberrant proliferation of cells responding to DNA
damage or oncogenic signaling, a program mediated predomi-
nantly by tumor suppressors such as p53, p16, and Rb (Narita
and Lowe, 2005). We had previously linked p63 deficiency to
cellular senescence (Keyes et al., 2005) and more recently found
that TAp63 isoforms are essential inducers of OIS that halt both
the initiation and progression of Ras-driven p53-deficient tumors
in vivo (Guo et al., 2009). This ability of TAp63 to induce OIS in
mesenchymal cells contrasts vividly with the potent senes-
cence-inhibitory activity of DNp63a in epithelial cells presented
here, underscoring the unique role of different p63 isoforms in
distinct cellular contexts.
We used an unbiased genetic screen to uncover mechanisms
by which DNp63a bypasses senescence and induces stem-likeCproliferation. This approach revealed a number of interesting
candidates, including stem cell-associated genes (Brca1,
Geminin, Lsh, TGF-b), DNA damage and repair genes (Brca1,
Chk1, Exo1, Rad51, Cdc6), and others, suggesting that
DNp63a affects cellular proliferation on several levels. Interest-
ingly, mouse models deficient for three of these candidates
have phenotypes of cellular senescence or organismal aging:
Lsh (Sun et al., 2004), Exo1 (Schaetzlein et al., 2007), and
Brca1 (Cao et al., 2003). Here we identify Lsh, a chromatin re-
modeler of the SNF2 family, as a p63-induced protein required
for DNp63a-mediated senescence bypass. Lsh plays a key
role in senescence and aging, with Lsh-deficient mice exhibiting
either postnatal lethality (Geiman et al., 2001) or aberrant aging
and enhanced cellular senescence (Sun et al., 2004). Lsh regu-
lates DNA methylation and transcriptional silencing (Muegge,
2005), as indicated by the fact that its deficiency causes DNA hy-
pomethylation, altered histone modification, and alterations in
heterochromatin (Dennis et al., 2001; Muegge, 2005). In partic-
ular, Lsh is required for methylation-induced silencing of repeat
elements and transposons in the pericentromeric regions
(Huang et al., 2004; Sun et al., 2004) and also causes transcrip-
tional silencing of individual loci including Cdkn1c/p57 (Sun
et al., 2004) and Hox (Xi et al., 2007) genes. Lsh functions by re-
cruiting DNAmethyltransferases (Myant and Stancheva, 2008) or
through direct interaction withmembers of the Polycomb repres-
sive complex 1 (Xi et al., 2007). Although the mechanism by
which DNp63a-driven Lsh expression facilitates senescence
bypass and tumor development remain to be elucidated, a recent
report that Lsh is overexpressed in human HNSCC (Gemenetzi-
dis et al., 2009) supports our finding that DNp63a promotes
tumorigenesis via induction of Lsh-mediated bypass of OIS.
Another major finding of this work is that DNp63a’s oncogenic
role is associated with its ability to maintain the K15-positive
stem cell population. There is accumulating evidence that p63,
and in particular the DNp63a isoform, maintains the proliferative
capacity of epithelial stem cells of the skin, thymus, prostate,
breast, and eye (Pellegrini et al., 2001; Senoo et al., 2007; Xin
et al., 2007). However, the mechanisms by which p63 mediates
stem-like proliferation has not been established. Our identifica-
tion of Lsh, a chromatin-remodeling protein robustly expressed
in human embryonic stem cells (Assou et al., 2007), as
a DNp63a target suggests that p63 plays a role in epigenetic
regulation of stemness. Our findings also raise interesting ques-
tions regarding the role of stem or stem-like cells in tumorigen-
esis. In some tumors, the cell of origin is suggested to be a normal
somatic stem cell that has acquired mutations that allow it to
transform (Barker et al., 2009). In other tumors, however, the
cell of origin is suggested to be a more mature progenitor or
committed daughter cell that acquired mutations that make it
function more like a stem cell, thereby promoting tumorigenesis
(Jamieson et al., 2004). Our data support the fact that DNp63a
promotes aberrant proliferation of the K15 population of stem
cells in the skin, providing evidence that these are the tumor-initi-
ating population in SCC. In contrast with tumors such as pancre-
atic intraepithelial neoplasia and malignant astrocytomas, in
which Nestin-positive stem/progenitor cells are the source of
malignancy after oncogene activation or tumor-suppressor
loss (Alcantara Llaguno et al., 2009; Carrie`re et al., 2007; Dai
et al., 2001), our data suggest that DNp63a does not target theell Stem Cell 8, 164–176, February 4, 2011 ª2011 Elsevier Inc. 173
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affects a multipotent stem cell population and identification of
Lsh as a critical component of senescence bypass concomitant
with the acquisition/maintenance of stem-like features and
tumorigenesis suggests that epigenetic events play a critical
role in this process.
EXPERIMENTAL PROCEDURES
Keratinocyte Culture, Retroviral Infection, and Hairpin Design
Primary keratinocyte cultures were prepared as previously described (Keyes
et al., 2005). Differentiation was induced in media + 1.5 mM CaCl2 for
6–96 hr. For GFP-stem cell assays, primary keratinocytes from K15-GFP
(Morris et al., 2004) and Nestin-GFP transgenic (Mignone et al., 2004, 2007)
mice were prepared and infected as described. GFP quantitation in
Nestin-GFP and K15-GFP models was performed with Guava Easycyte
(Guava Technologies) and LSRII (BD Biosciences) FACS analyzer and FloJo
software, respectively. Human HNSCC cells were previously described
(Rocco et al., 2006). Western blotting and qRT-PCR were performed as
described (Keyes et al., 2005) with primers listed (Supplemental Experimental
Procedures). SA-b-gal activity was performed as described (Keyes et al.,
2005). Mouse Genome 430A 2.0 microarrays (Affymetrix) were used. siRNA’s
targeting Lsh (CCGTCGGAAATTAGTAAAGAA) were designed with the Bio-
predsi (http://www.biopredsi.org/design.html) website, cloned into LMP
vectors (Dickins et al., 2005), evaluated for efficiency in mouse embryonic
fibroblasts (mefs), and assessed by western blotting 2 days after drug selec-
tion. Keratinocyte infections were performed essentially as described previ-
ously (Keyes et al., 2005). In brief, retrovirus was produced by transiently trans-
fecting the ecotropic Phoenix packaging cell line (G. Nolan, Stanford
University, Stanford, CA). Two days after transfection, viral supernatant was
collected, filtered, and added to the keratinocyte cultures. Two infections of
2 hr each were performed. After 2 days, keratinocytes were drug selected ac-
cording to the different selection markers.
Three-Dimensional Tissue Culture
Three-dimensional tissue culture was performed as previously described
(Aranda et al., 2006), with 2.5% collagen:matrigel (BD Biosciences) 1:1 mix
as matrix. 5 3 103 cells were seeded onto 8-well chamber slides (BD Falcon)
and fresh media containing collagen:matrigel was added every 2 days.
Morphology was assessed by phase microscopy. For immunofluorescence,
cultures were fixed and stained as described (Aranda et al., 2006), with anti-
K14 polyclonal antibody AF64 (Covance Research Products Inc.) and Alexa
Fluor secondary antibodies (Molecular Probes).
Tumor Study
Cells were injected subcutaneously into athymic nude mice as outlined in
Table S1. Tumor development was monitored by whole-body GFP imaging.
Histopathology was performed by H.V. Immunohistochemistry was performed
as described (Keyes et al., 2005). Animals were housed and handled according
to Barcelona Biomedical Research Park Animal Facility (PRBB), Cold Spring
Harbor Institutional Animal Care and Use Committee (IACUC), and Association
for Accreditation of Laboratory Animal Care International (AAALAC) policies.
Chromatin Immunoprecipation
RDN keratinocytes were fixed in 1% formaldehyde,10 min, room temperature,
crosslinking stopped in 0.125Mglycine/PBS, washed in cold PBS, centrifuged
2000 rpm, 2 min, and resuspended to 3 3 106 cells/ml in cell lysis buffer
(5mMHEPES [pH 7.9], 85mMKCl, 0.5%NP40) + protease inhibitors and incu-
bated on ice, 15 min. Homogenates were centrifuged at 5000 rpm, 5 min, 4C,
pellets resuspended in nuclear lysis buffer (50 mM Tris [pH 8], 10 mM EDTA
[pH 8], 1% SDS) + protease inhibitors and incubated on ice, 20 min. Nuclear
lysates were sonicated with a Diagenode Sonicator and centrifuged at
12,000 rpm, 10 min, 4C. Supernatants were diluted in IP buffer (150 mM
NaCl, 20 mM Tris [pH 8], 2 mM EDTA) with Protein-A/G beads (previously pre-
blocked with sheared salmon sperm DNA and BSA and precleared for >2 hr at
4C). Preblocked protein A/G beads were incubated with 4A4 antibody (Santa
Cruz, SC-8431) or a-integrin 1a antibody (Santa Cruz, SC-8978) in IP buffer174 Cell Stem Cell 8, 164–176, February 4, 2011 ª2011 Elsevier Inc.(2 hr, 4C), centrifuged, washed with IP buffer, and incubated with precleared
chromatin overnight at 4C. Beads were pelleted, washed sequentially with
low salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris [pH 8],
150 mM NaCl), high salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA,
20 mM Tris [pH 8], 500 mM NaCl), LiCl buffer (0.25 M LiCl, 1% NP40, 1%
Na+2 deoxycholate, 1 mM EDTA, 10 mM Tris [pH 8]), and TE buffer. Chromatin
was eluted in elution buffer (100 mM NaHCO3, 1% SDS) overnight at 65
C,
collected by centrifugation, and incubated with proteinase K (30 min, 37C).
DNA was extracted and PCR amplified with specific primers (see Figure S5,
Supplemental Experimental Procedures).
p63 consensus-binding sitesWDDCNDGHHD {1-25}WDDCNDGHHDwere
identified with modifications of previously published motifs (Ortt and Sinha,
2006; Yang et al., 2006). The Lsh promoter was identified with the TRED data-
base (http://rulai.cshl.edu/cgi-bin/TRED/tred.cgi?process=home) and p63
consensus sites were identified 1300 bp upstream of the TSS (38284774
of NM_008234) and 2500 bp upstream of the TSS (47110038 of
NT_030059) of mouse and human LSH, respectively (see Figure S5).SUPPLEMENTAL INFORMATION
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